A detailed history of Woodline Partners LP transactions in Exscientia PLC stock. As of the latest transaction made, Woodline Partners LP holds 1,135,228 shares of EXAI stock, worth $5.24 Million. This represents 0.06% of its overall portfolio holdings.

Number of Shares
1,135,228
Previous 1,655,890 31.44%
Holding current value
$5.24 Million
Previous $9.47 Million 38.88%
% of portfolio
0.06%
Previous 0.09%

Shares

11 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q2 2024

Aug 14, 2024

SELL
$3.99 - $6.04 $2.08 Million - $3.14 Million
-520,662 Reduced 31.44%
1,135,228 $5.79 Million
Q1 2024

May 15, 2024

BUY
$5.3 - $7.51 $68,624 - $97,239
12,948 Added 0.79%
1,655,890 $9.47 Million
Q4 2023

Feb 14, 2024

SELL
$4.35 - $6.88 $3.47 Million - $5.49 Million
-798,335 Reduced 32.7%
1,642,942 $10.5 Million
Q3 2023

Nov 14, 2023

BUY
$4.52 - $8.9 $7.57 Million - $14.9 Million
1,673,928 Added 218.14%
2,441,277 $11 Million
Q2 2023

Aug 14, 2023

BUY
$4.79 - $8.3 $693,069 - $1.2 Million
144,691 Added 23.24%
767,349 $4.54 Million
Q1 2023

May 15, 2023

SELL
$5.3 - $10.93 $2.13 Million - $4.39 Million
-401,501 Reduced 39.2%
622,658 $3.3 Million
Q4 2022

Feb 14, 2023

SELL
$4.1 - $8.94 $1.15 Million - $2.51 Million
-280,847 Reduced 21.52%
1,024,159 $5.46 Million
Q3 2022

Nov 14, 2022

BUY
$7.27 - $12.92 $7.53 Million - $13.4 Million
1,035,457 Added 384.14%
1,305,006 $10.7 Million
Q2 2022

Aug 15, 2022

SELL
$6.92 - $15.97 $1.94 Million - $4.48 Million
-280,478 Reduced 50.99%
269,549 $2.94 Million
Q1 2022

May 16, 2022

SELL
$11.52 - $22.05 $19,399 - $37,132
-1,684 Reduced 0.31%
550,027 $7.92 Million
Q4 2021

Feb 14, 2022

BUY
$17.63 - $27.1 $9.73 Million - $15 Million
551,711 New
551,711 $10.9 Million

Others Institutions Holding EXAI

About Exscientia plc


  • Ticker EXAI
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 122,461,000
  • Market Cap $566M
  • Description
  • Exscientia plc, an artificial intelligence-driven pharmatech company, engages in discovering, designing, and developing drugs. The company offers end-to-end solution of artificial intelligence (AI) and technologies for target identification, drug candidate design, translational models, and patient selection. In addition, the company focuses on s...
More about EXAI
Track This Portfolio

Track Woodline Partners LP Portfolio

Follow Woodline Partners LP and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Woodline Partners LP, based on Form 13F filings with the SEC.

News

Stay updated on Woodline Partners LP with notifications on news.